the invention describes a stable immunogenic protein having multiple cysteines molecules wherein the protein is having stability up to two years and purity more than 98 % particularly rpvrii and / or rpff2 . it also discloses a method for producing said immunogenic protein comprising the following steps : culturing the host e . coli cells containing a desired recombinant gene construct comprising a codon optimized gene sequence of rpvrii and / or rpff2 to produce cells in high density ; inducing expression rpvrii and / or rpff2 as inclusion bodies ; harvesting the cells and isolating the said inclusion bodies ; separating rpvrii and / or rpff2 from inclusion bodies by repeated sequential washing and solubilizing with chaotrophic agents comprising guanidine hydrochloride and / or urea ; purifying the protein by subjecting to metal - chelate affinity chromatography ; re - folding of the purified rpvrii and / or rpff2 obtained in step e ) with a redox system to recover a high yield of the soluble protein , followed by further purifying the desired protein by removing impurities by subjecting to chromatography . further the invention discloses formulation comprising rpvrii or rpff2 , preferably being lyophilized using polysaccharides preferably sucrose , lactose , and pharmaceutically acceptable adjuvants such as aluminum hydroxide , aluminum phosphate , cpg nucleotides , non - cpg nucleotides , montanide isa - 720 , mf - 59 , mono - phosphoryl lipid - a and qs - 21 .